Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population

Bone Marrow Transplant. 2021 Jul;56(7):1761-1763. doi: 10.1038/s41409-021-01280-3. Epub 2021 Apr 12.

Authors

Lauren C Shapiro¹, Jennat Mustafa¹, Amanda Lombardo¹, Fariha Khatun¹, Felisha Joseph¹, Kailyn Gillick¹, Anjali Naik¹, Richard Elkind¹, Michelly Abreu¹, Karen Fehn¹, Alyssa de Castro², Kith Pradhan¹, Donika Binakaj¹, Randin Nelson³, Monika Paroder³, Joan Uehlinger³, Kira Gritsman¹, R Alejandro Sica¹, Noah Kornblum¹, Aditi Shastri¹, Ioannis Mantzaris¹, Lizamarie Bachier-Rodriguez¹, Amit Verma¹, Ira Braunschweig¹, Mendel Goldfinger⁴

Affiliations

¹ Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
² Department of Pharmacy, Montefiore Medical Center, Bronx, NY, USA.
³ Department of Pathology, Montefiore Medical Center, Bronx, NY, USA.
⁴ Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. [email protected].

PMID: 33846558
DOI: 10.1038/s41409-021-01280-3

No abstract available

Publication types

Letter

MeSH terms

Aged
Antigens, CD19 / therapeutic use
Biological Products
Humans
Immunotherapy, Adoptive*
Lymphoma, Large B-Cell, Diffuse* / drug therapy

Substances

Antigens, CD19
Biological Products
axicabtagene ciloleucel